A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
Key facts
- Who runs it
- ModernaTX, Inc.
- Where
- Akron, Baton Rouge, Blackfoot, Brookline, Columbus, Dublin, Gulfport, Hendersonville, Hialeah, Houston, Jupiter, Lincoln, McKinney, Miami, Norfolk, Orlando, Philadelphia, Prairieville, River Forest, Riverside, Rolling Hills Estates, San Diego, Scottsdale, Southfield, Spartanburg, Springfield, Stockbridge, Sugar Land, Tampa, Tomball, Tulsa, and Wilmington, United StatesSee the 34 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 1,900 people enrolled
- Started
- 25 Sept 2023
- Ended
- 7 Jun 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- Placebo
- mRNA-1345
- Fluzone HD
- Record updated
- 30 July 2025
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by:; Absence of changes in medical therapy within 60 days of Day 1 due to treatment failure or toxicity,; Absence of serious or significant medical events within 30 days of Day 1, and; Absence of known, current, and life-limiting diagnoses which, in the opinion of the Investigator, would make completion of the protocol unlikely
- A participant assigned female at birth is eligible to participate if they are postmenopausal or not a person of childbearing potential
Who cannot take part
- Participant has tested positive for influenza or RSV by local health authority-approved testing methods ≤6 months prior to Day 1
- Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to study injections (Day 1 and Day 22) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after study injections
- Participant has received a seasonal influenza vaccine or any other investigational influenza vaccine ≤6 months prior to Day 1
- Participant has received any RSV vaccine (authorized/approved by local health agency or investigational) prior to Day 1; Note: Other protocol-defined inclusion and/or exclusion criteria may apply
- Reported history of congenital or acquired immunodeficiency, immunosuppressive condition or immune-mediated disease, asplenia, or recurrent severe infections
- Close contact with someone with laboratory-confirmed influenza and/or RSV infection or with someone who has been treated with antiviral therapies for influenza (for example, Tamiflu®) within the past 5 days prior to Day 1
Where in United States
- Synexus AES - AkronAkron, United States
- Velocity Clinical Research - Baton RougeBaton Rouge, United States
- Bingham Memorial HospitalBlackfoot, United States
- DM Clinical Research - BrooklineBrookline, United States
- Centricity ResearchColumbus, United States
- West Coast Research LLCDublin, United States
- DelRicht Research at Gulfport MemorialGulfport, United States
- Delricht MoyerHendersonville, United States
- NeoClinical ResearchHialeah, United States
- DM Clinical Research - HoustonHouston, United States
- Health Awareness, IncJupiter, United States
- Be Well Clinical Studies LLCLincoln, United States
- DELRICHT RESEARCH at ZOMNIR FAMILY MEDICINEMcKinney, United States
- South Florida Research Center, Inc.Miami, United States
- Suncoast Research Associates, LLCMiami, United States
- Velocity Clinical Research - NorfolkNorfolk, United States
- Headlands Research OrlandoOrlando, United States
- DM Clinical Research - PhiladelphiaPhiladelphia, United States
- DelRicht Research @ Neighborhood HealthPrairieville, United States
- DM Clinical Research - River ForestRiver Forest, United States
- Artemis Institute for Clinical ResearchRiverside, United States
- Peninsula Research Associates PraRolling Hills Estates, United States
- Acclaim Clinical ResearchSan Diego, United States
- Headlands Research, Inc.Scottsdale, United States
- Scottsdale Clinical TrialsScottsdale, United States
- DM Clinical Research - SouthfieldSouthfield, United States
- Spartanburg Medical ResearchSpartanburg, United States
- DelRicht ResearchSpringfield, United States
- Clinical Research Atlanta - HeadlandsStockbridge, United States
- Javara Inc. /Privia Medical Group Gulf Coast, PLLCSugar Land, United States
- New Tampa Health, IncTampa, United States
- DM Clinical ResearchTomball, United States
- Delricht TateTulsa, United States
- Trial Management Associates, LLCWilmington, United States
About the trial
What the trial wants to find out
The main purpose of this study is to evaluate the safety and immunogenicity of mRNA-1345 RSV vaccine when coadministered with a high dose (HD) quadrivalent seasonal influenza vaccine (Fluzone HD) in adults ≥65 years of age. The study will examine the impact of Fluzone HD on the immune response to mRNA-1345 against RSV-A and RSV-B, as well as the impact of mRNA-1345 on the immune response to Fluzone HD against 4 vaccine-matched Influenza A and B strains.
The 2 groups in the trial
- Fluzone HD + mRNA-1345Treatment being tested
Participants will receive Fluzone HD + mRNA-1345 by intramuscular (IM) injection on Day 1 followed by placebo by IM injection on Day 22.
Treatment: Placebo, mRNA-1345, and Fluzone HD
- Fluzone HD Followed by mRNA-1345Treatment being tested
Participants will receive Fluzone HD + placebo by IM injection on Day 1 followed by mRNA-1345 by IM injection on Day 22.
Treatment: Placebo, mRNA-1345, and Fluzone HD
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults ≥65 Years of Age
- Publications
- Record updated
- 30 July 2025